Drugs / allogenic amniotic fluid mesenchymal stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06386679 | Aug → Nov 2023 | osteoarthritis, knee | Siriraj Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogenic amniotic fluid mesenchymal stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06386679 ↗ |
| Known as | AFCC | “Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA).” NCT06386679 ↗ |
| Modality | Cell therapy | “Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC)” NCT06386679 ↗ |
| Route | Other | “Intra-articular AFCC injection” NCT06386679 ↗ |